CBG

This page is only a stub and has not yet been reviewed. Any and all facts within are questionable. Please feel free to fill in gaps where you know how to fill them by editing this page.

Cannabinoid (minor), phytocannabinoid, precursor cannabinoid

Cannabigerol

Cannabigerol (CBG) is a minor phytocannabinoid of cannabis and, in its acidic form cannabigerolic acid (CBGA), the biosynthetic precursor from which the plant produces tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromenic acid (CBCA) by enzyme-specific cyclization. Mature flower typically contains less than 1% CBG because most CBGA has already been converted into the downstream cannabinoids; CBG-dominant chemovars (the chemovar type IV classification) are an exception. CBG is non-psychoactive at typical doses and has weak direct cannabinoid-receptor activity; its preclinical pharmacology is dominated by non-CB targets including alpha-2 adrenergic agonism, 5-HT1A antagonism, and modulation of TRPM8 and TRPV channels. Clinical evidence remains preliminary; CBG-rich extracts have been investigated for inflammatory bowel disease, glaucoma, and antibacterial activity, but no CBG-containing product has been approved for any indication.

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary

Classes

Cannabinoid (minor), phytocannabinoid, precursor cannabinoid

Common uses

Pharmacy

Pharmacology

Purported mechanism

Weak partial agonist at CB1 and CB2; alpha-2 adrenergic agonist; 5-HT1A antagonist; multiple TRP channel effects.